全部 标题 作者
关键词 摘要

PLOS ONE  2011 

Profiling of Substrate Specificities of 3C-Like Proteases from Group 1, 2a, 2b, and 3 Coronaviruses

DOI: 10.1371/journal.pone.0027228

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Coronaviruses (CoVs) can be classified into alphacoronavirus (group 1), betacoronavirus (group 2), and gammacoronavirus (group 3) based on diversity of the protein sequences. Their 3C-like protease (3CLpro), which catalyzes the proteolytic processing of the polyproteins for viral replication, is a potential target for anti-coronaviral infection. Methodology/Principal Findings Here, we profiled the substrate specificities of 3CLpro from human CoV NL63 (group 1), human CoV OC43 (group 2a), severe acute respiratory syndrome coronavirus (SARS-CoV) (group 2b) and infectious bronchitis virus (IBV) (group 3), by measuring their activity against a substrate library of 19×8 of variants with single substitutions at P5 to P3' positions. The results were correlated with structural properties like side chain volume, hydrophobicity, and secondary structure propensities of substituting residues. All 3CLpro prefer Gln at P1 position, Leu at P2 position, basic residues at P3 position, small hydrophobic residues at P4 position, and small residues at P1' and P2' positions. Despite 3CLpro from different groups of CoVs share many similarities in substrate specificities, differences in substrate specificities were observed at P4 positions, with IBV 3CLpro prefers P4-Pro and SARS-CoV 3CLpro prefers P4-Val. By combining the most favorable residues at P3 to P5 positions, we identified super-active substrate sequences ‘VARLQ↓SGF’ that can be cleaved efficiently by all 3CLpro with relative activity of 1.7 to 3.2, and ‘VPRLQ↓SGF’ that can be cleaved specifically by IBV 3CLpro with relative activity of 4.3. Conclusions/Significance The comprehensive substrate specificities of 3CLpro from each of the group 1, 2a, 2b, and 3 CoVs have been profiled in this study, which may provide insights into a rational design of broad-spectrum peptidomimetic inhibitors targeting the proteases.

References

[1]  van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, et al. (2004) Identification of a new human coronavirus. Nat Med 10: 368–373.
[2]  Hamre D, Procknow JJ (1966) A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 121: 190–193.
[3]  Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, et al. (2005) Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 79: 884–895.
[4]  Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, et al. (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362: 263–270.
[5]  Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319–1325.
[6]  Cheever FS, Daniels JB, Pappenheimer AM, Bailey OT (1949) A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. J Exp Med 90: 181–210.
[7]  Binn LN, Lazar EC, Keenan KP, Huxsoll DL, Marchwicki RH, et al. (1974) Recovery and characterization of a coronavirus from military dogs with diarrhea. Proc Annu Meet U S Anim Health Assoc. pp. 359–366.
[8]  Poon LL, Chu DK, Chan KH, Wong OK, Ellis TM, et al. (2005) Identification of a novel coronavirus in bats. J Virol 79: 2001–2009.
[9]  Beaudette FR, Hudson CB (1937) Cultivation of the virus of infectious bronchitis. J Am Vet Med Assoc 90: 51–58.
[10]  Doyle LP, Hutchings LM (1946) A transmissible gastroenteritis virus in pigs. J Am Vet Assoc 108: 257–259.
[11]  Tyrrell DA, Bynoe ML (1966) Cultivation of viruses from a high proportion of patients with colds. Lancet 1: 76–77.
[12]  Woo PC, Lau SK, Huang Y, Yuen KY (2009) Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med (Maywood) 234: 1117–1127.
[13]  Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, et al. (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 331: 991–1004.
[14]  Gorbalenya AE, Snijder EJ, Spaan WJ (2004) Severe acute respiratory syndrome coronavirus phylogeny: toward consensus. J Virol 78: 7863–7866.
[15]  Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE (2010) Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48: 2940–2947.
[16]  Dominguez SR, Robinson CC, Holmes KV (2009) Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado. J Med Virol 81: 1597–1604.
[17]  Cavanagh D (2007) Coronavirus avian infectious bronchitis virus. Vet Res 38: 281–297.
[18]  Ignjatovic J, Sapats S (2000) Avian infectious bronchitis virus. Rev Sci Tech 19: 493–508.
[19]  Lin CW, Tsai CH, Tsai FJ, Chen PJ, Lai CC, et al. (2004) Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs. FEBS Lett 574: 131–137.
[20]  Yang H, Xie W, Xue X, Yang K, Ma J, et al. (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3: e324.
[21]  Li SY, Chen C, Zhang HQ, Guo HY, Wang H, et al. (2005) Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 67: 18–23.
[22]  Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, et al. (2004) Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A 101: 10012–10017.
[23]  Chen L, Gui C, Luo X, Yang Q, Gunther S, et al. (2005) Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 79: 7095–7103.
[24]  Fan K, Ma L, Han X, Liang H, Wei P, et al. (2005) The substrate specificity of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun 329: 934–940.
[25]  Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, et al. (2007) Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry 46: 8744–8752.
[26]  Chuck CP, Chong LT, Chen C, Chow HF, Wan DC, et al. (2010) Profiling of substrate specificity of SARS-CoV 3CLpro. PLoS ONE 5: e13197.
[27]  Hegyi A, Ziebuhr J (2002) Conservation of substrate specificities among coronavirus main proteases. J Gen Virol 83: 595–599.
[28]  Lee S, Tikhomirova A, Shalvardjian N, Chalikian TV (2008) Partial molar volumes and adiabatic compressibilities of unfolded protein states. Biophys Chem 134: 185–199.
[29]  Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157: 105–132.
[30]  Chou PY, Fasman GD (1978) Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 47: 45–148.
[31]  Xue X, Yu H, Yang H, Xue F, Wu Z, et al. (2008) Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol 82: 2515–2527.
[32]  Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300: 1763–1767.
[33]  Zhao Q, Li S, Xue F, Zou Y, Chen C, et al. (2008) Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. J Virol 82: 8647–8655.
[34]  Jenkins GM, Rambaut A, Pybus OG, Holmes EC (2002) Rates of molecular evolution in RNA viruses: a quantitative phylogenetic analysis. J Mol Evol 54: 156–165.
[35]  Lai MM (1992) RNA recombination in animal and plant viruses. Microbiol Rev 56: 61–79.
[36]  Pasternak AO, Spaan WJ, Snijder EJ (2006) Nidovirus transcription: how to make sense...? J Gen Virol 87: 1403–1421.
[37]  Duffy S, Shackelton LA, Holmes EC (2008) Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 9: 267–276.
[38]  Zhu L, George S, Schmidt MF, Al-Gharabli SI, Rademann J, et al. (2011) Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. doi:10.1016/j.antiviral.2011.08.001.

Full-Text

comments powered by Disqus